Reporting and Outcomes of Brachytherapy for Gynecologic Reirradiation: A Systematic Review.
Int J Radiat Oncol Biol PhysJun 9, 2026 (epub)
Sabrina Reichl, Christian Kirisits, Jacob Christian Lindegaard et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated gynecological reirradiation using brachytherapy (GRIB) in 1978 patients from 50 studies, primarily retrospective. The findings indicate encouraging local control rates of 35%-87% at 1 year and 26%-59% at 5 years, but highlight significant variability in reporting practices and treatment protocols.
Key findings
- Local control rates for GRIB were 35%-87% at 1 year and 26%-59% at 5 years.
- Overall survival rates ranged from 52%-83% at 1 year and 34%-54% at 5 years.
- Grade 3 or 4 late toxicity rates varied from 0% to 33% across studies.
- 92% of the studies analyzed were retrospective with a mean sample size of 28.2 patients.
Why it matters
Understanding the effectiveness and safety of GRIB is crucial for clinicians managing recurrent gynecologic cancers. The variability in reporting and outcomes underscores the need for standardized practices to improve patient care and treatment decisions.